Vigabatrin and lamotrigine in refractory epilepsy

Iwona Stolarek, Jacqueline Blacklaw, Gerard Forrest, Martin J Brodie

Abstract
Epilepsy arises from an imbalance of inhibitory and excitatory influences in the brain. Vigabatrin (VIG) decreases the breakdown of the inhibitory neurotransmitter γ-aminobutyric acid, whereas lamotrigine (LTG) reduces presynaptic excitatory amino acid release. 22 patients with refractory epilepsy, treated with an anticonvulsant regimen containing VIG, entered a balanced, double blind, placebo controlled, crossover trial of additional LTG. Treatment periods of 12 weeks (25 mg, 50 mg, 100 mg LTG twice daily for four weeks at each dose, and matched placebo) were followed by wash out intervals of four weeks. 14 of the 20 patients completing the study improved, resulting in a significant fall in seizure days and numbers. Analysis of seizure type confirmed a beneficial effect on partial and secondary generalised tonic-clonic seizures. At the highest LTG dose (200 mg daily) there was a median fall of 37% in seizure count with nine (45%) patients reporting >50% reduction. Three of these patients were seizure free during this month of treatment. Side effects were minimal throughout the study. Concentrations of other antiepileptic drugs, including those of carbamazepine 10,11-epoxide, were not modified by LTG. This study suggests a substantial efficacy for a regimen containing VIG and LTG. Combinations of drugs with complementary modes of action may provide a rational pharmacological approach to the management of refractory epilepsy.

(J Neurol Neurosurg Psychiatry 1994;57:921–924)

Seizures follow abnormal synchronisation and amplification of neuronal firing in electrically unstable areas of the brain. They may arise from an imbalance of inhibitory and excitatory influences at a cellular level, resulting in either generation of electrical activity or in prevention of its inhibition.1 The major inhibitory neurotransmitter in the human brain is γ-aminobutyric acid (GABA) and the principal fast excitatory neurotransmitter is glutamate.

Two new antiepileptic drugs, vigabatrin (VIG) and lamotrigine (LTG), redress this presumed chemical imbalance, the first by increasing brain GABA and the second by decreasing presynaptic excitatory amino acid release.2 Anecdotal reports about three patients suggested substantial efficacy for VIG and LTG in combination, when individual treatment with either drug had failed.3,4 Our objective was to explore this finding further with a placebo controlled, dose ranging study of additional LTG in patients with refractory epilepsy and receiving an anticonvulsant regimen containing VIG. As neither drug has a product licence for use as monotherapy, it was not possible to undertake the study in patients receiving vigabatrin alone.

Patients and methods

PATIENTS
Twenty two patients with complex partial seizures with or without secondary generalisation were recruited. All had reported a minimum of three seizures a month for the previous three months despite a stable regimen of anticonvulsant treatment. Nine and 13 patients took VIG with one or two other antiepileptic drugs respectively. All gave written informed consent to their participation in the trial, which had local ethics committee approval.

PROTOCOL
This was a randomised, double blind, placebo controlled, crossover, dose ranging study of additional LTG. After an initial four week run in, two 12 week treatment periods (25 mg, 50 mg, and 100 mg LTG twice daily for four weeks each and matched placebo) were followed by four-week washout intervals. Patients were examined at weeks 0, 4, 8, and 12 during both treatments. Appointment times were individualised and kept constant. Medication was taken at the same times each day. Compliance was checked by a tablet count.

Seizure types and numbers were recorded on standard charts with which the patients were familiar. Venous blood was withdrawn at each visit for measurement of LTG, VIG, and other antiepileptic drug concentrations. Samples were centrifuged immediately and serum was stored at −20°C for batch analysis.

SIDE EFFECTS
At each visit spontaneous reporting of adverse events was encouraged. Patients were also asked about the presence or absence of 11 specific symptoms, five of which (dry mouth, itch, flushing, palpitations, ankle swelling) were included as controls. The other six
Median seizure numbers in 20 patients with refractory epilepsy after treatment with LTG and matched placebo. Horizontal bars are 95% CIs of the differences.

(unsteadiness, headache, dizziness, double vision, nausea, tremor) were commonly associated with anticonvulsant treatment. Also, 10 cm visual analogue scales measuring subjective sedation, concentration, memory, and mood were completed by the patients at each visit. At the end of the study each patient was invited to state a preference for one or other treatment period before the code was broken.

DRUG ASSAYS
Vigabatrin was extracted from plasma into ethylacetate, heated with dansyl chloride at high pH to form a fluorescent derivative, and measured by high performance liquid chromatography (HPLC) with phenylGABA as internal standard. The interassay coefficient of variation (CV) over the range 1–100 mg/l was 5% and the lower limit of detection was 0.1 mg/l. Lamotrigine was extracted into ethyl acetate from plasma with 2M sodium hydroxide and measured by HPLC with BWA 725C (Wellcome Laboratories, UK) as internal standard. The interassay CV over the range 0.5–5 mg/l was 6% with a lower limit of detection of 0.25 mg/l. Carbamazepine, sodium valproate, phenytoin, and phenobarbitone (in patients taking primidone) concentrations were measured by enzyme immunoassay (Emit, Syva, Palo Alto, USA). The active metabolite, carbamazepine 10, 11 epoxide, was determined by HPLC with 5-(p methylphenyl) 1–5-phenyl hydantoin as internal standard.

STATISTICS

Statistical analysis of seizure data, adverse effects, and antiepileptic drug concentrations was performed with the Wilcoxon rank test for matched pairs. The 95% confidence intervals (95% CIs) for the differences were calculated around median values with the Minstat statistical package. Mann-Whitney analysis for an order effect was carried out for total, partial, and generalised seizures.

Results

Patients

Twenty patients (eight men, 12 women) completed the trial. One withdrew due to transport difficulties in attending the hospital and another because of side effects (tiredness, dizziness, sore throat, emotional lability, irritability, weepiness, depression) while taking the placebo. Equal numbers of patients were randomised first to both arms of the study and there was no evidence of an order effect for any of the data.

Seizures

There was a significant reduction in seizure days during LTG treatment compared with placebo (median 5–5, p < 0.01, 95% CI −10 to −1.5), particularly at the highest dose (median 2–5 days, p < 0.05, 95% CI −5 to 0). Seizure numbers were reduced overall by 23% (figure, p < 0.005, 95% CI −15.5 to −2). Subtype analysis showed a fall in partial (n = 20, median 3, p < 0.02, 95% CI −13 to −0.5) and secondary generalised tonic-clonic seizures (n = 15, median 1.5, NS, 95% CI −3.5 to 0.5) (table 1). At the highest LTG dose (200 mg daily) there was an overall reduction of 37% in seizure numbers with nine (45%) patients reporting a fall of more than 50% compared with the equivalent placebo phase (table 2). Three patients remained seizure free during this month of treatment.

As the LTG dosage was titrated, results in the phases (39/60) during which LTG plasma concentrations exceeded 1 mg/l were compared with the equivalent periods on placebo. This analysis excluded data from 15 patients during phase 1 (LTG 25 mg twice daily) and seven patients during phase 2 (50 mg twice daily). Overall, there was a fall of 30% in seizure count. Sixteen patients improved with seven (35%) reporting >50% reduction. A significant fall was found for total (median 4.5, p < 0.01, 95% CI −8.5 to −2.0) and secondary generalised (median 2, p < 0.02, 95% CI −3.5 to 0) seizure numbers. The reduction in partial seizures failed to reach significance (median 2, NS, 95% CI −6.5 to +0.5).

Table 1 Median seizure numbers (range) and reductions (95% CIs of the difference) in 20 patients with refractory epilepsy receiving adjunctive LTG and matched placebo

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LTG</th>
<th>Reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>8.0 (0–50)</td>
<td>8.5 (0–41)</td>
<td>1.3 (−1 to +4.0)</td>
</tr>
<tr>
<td>Phase 1</td>
<td>9.5 (1–66)</td>
<td>6.5 (0–36)</td>
<td>2.5 (−5 to +0.5)</td>
</tr>
<tr>
<td>Phase 2</td>
<td>8.0 (0–72)</td>
<td>5.0 (0–60)</td>
<td>3.0 (−5 to −0.5)</td>
</tr>
<tr>
<td>Phase 3</td>
<td>24.0 (0–188)</td>
<td>18.5 (0–137)</td>
<td>6.2 (−4.5 to 2.0)</td>
</tr>
</tbody>
</table>

Partial seizures:

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LTG</th>
<th>Reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>7.0 (0–50)</td>
<td>4.0 (0–41)</td>
<td>3.0 (−4 to +1.0)</td>
</tr>
<tr>
<td>Phase 1</td>
<td>6.5 (0–60)</td>
<td>5.5 (0–36)</td>
<td>1.0 (−5 to +1.5)</td>
</tr>
<tr>
<td>Phase 2</td>
<td>6.5 (0–72)</td>
<td>4.5 (0–60)</td>
<td>2.0 (−7 to +1.0)</td>
</tr>
<tr>
<td>Phase 3</td>
<td>17.5 (0–186)</td>
<td>18.0 (0–137)</td>
<td>0.5 (−2 to −0.5)</td>
</tr>
</tbody>
</table>

Secondary generalised:

<table>
<thead>
<tr>
<th>Placebo</th>
<th>LTG</th>
<th>Reduction</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>5.0 (0–23)</td>
<td>2.5 (0–16)</td>
<td>2.5 (−3 to +0.5)</td>
</tr>
</tbody>
</table>

Phase 1, 25 mg LTG twice daily; phase 2, 50 mg LTG twice daily; phase 3, 100 mg LTG twice daily.

Table 2 Reduction in mean seizure counts and numbers of responders during adjunctive LTG vs placebo in 20 patients with refractory epilepsy

<table>
<thead>
<tr>
<th>No of responders</th>
<th>Seizure reduction</th>
<th>&lt;25% reduction</th>
<th>&lt;50% reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 (25 mg twice daily)</td>
<td>−6%</td>
<td>5 (25%)</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>Phase 2 (50 mg twice daily)</td>
<td>32%</td>
<td>4 (20%)</td>
<td>7 (35%)</td>
</tr>
<tr>
<td>Phase 3 (100 mg twice daily)</td>
<td>37%</td>
<td>3 (15%)</td>
<td>9 (45%)</td>
</tr>
<tr>
<td>Overall</td>
<td>25%</td>
<td>6 (30%)</td>
<td>4 (20%)</td>
</tr>
</tbody>
</table>
Table 3  Mean (SD) anticonvulsant concentrations (mg/l) in 20 patients receiving four weeks' adjunctive treatment with 100 mg LTG twice daily and matched placebo

<table>
<thead>
<tr>
<th>Anticonvulsant</th>
<th>No</th>
<th>Placebo</th>
<th>LTG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vigabatrin</td>
<td>20</td>
<td>26 (21)</td>
<td>26 (21)</td>
</tr>
<tr>
<td>Carbamazepine 10, 11 epoxide</td>
<td>15</td>
<td>6 (21)</td>
<td>7.6 (2-3)</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>5</td>
<td>1 (0.9)</td>
<td>1.2 (0.8)</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>3</td>
<td>14 (2.4)</td>
<td>14 (1.1)</td>
</tr>
</tbody>
</table>

SIDE EFFECTS
There were no significant differences in the numbers of spontaneous or requested side effects reported during the two treatment periods (spontaneous: LTG six, placebo seven; requested: LTG six, placebo seven). No one side effect was reported more often with LTG than placebo. Mean visual analogue scores for sedation, concentration, memory, and depression did not differ significantly after a month's treatment between LTG (100 mg twice daily) and matched placebo (data not shown). Sixteen patients preferred LTG treatment, whereas three of the remaining four chose placebo (p < 0.001).

CONCENTRATIONS
Concentrations of LTG (median [range]) after each treatment phase varied substantially among the patients (phase 1: 0.64 mg/l [0.34–2.7]; phase 2: 1.2 mg/l [0.47–4.1]; phase 3: 2.4 mg/l [1–7.9]). The mean LTG concentration in the nine patients reporting >50% seizure reduction during phase 3 was higher than in the 11 non-responders (3.2 mg/l v 2.1 mg/l), but not significantly so. No significant differences were found after the highest LTG dose for concentrations of concomitant anticonvulsants or of the active metabolite carbamazepine 10, 11 epoxide (table 3).

Discussion
Vigabatrin binds irreversibly to the enzyme GABA transaminase preventing GABA breakdown and increasing brain concentrations of this important inhibitory neurotransmitter. In placebo controlled trials, treatment with VIG produced a sustained reduction in seizure numbers in around 50% of patients with refractory epilepsy. Clinical studies with this drug, however, suggested better efficacy against partial than generalised tonic-clonic seizures.

Lamotrigine is a phenyltriazine compound that reduces presynaptic excitatory amino acid release by blocking voltage sensitive sodium channels, thus attenuating neuronal excitation. Eight double blind, placebo controlled, add on, crossover trials have investigated the efficacy of LTG in refractory epilepsy. Seven of these showed a significant reduction in total and partial seizure counts. In three, there were sufficient numbers of patients with secondary generalised tonic-clonic seizures to confirm a beneficial effect on this seizure type also.

Side effects during our present study were minimal with no statistical difference noted between LTG and placebo. Mean linear analogue scores for sedation, concentration, memory, and depression were no different after a month's treatment with highest LTG dose and placebo. Mood lifting effects with LTG have been reported anecdotally in several studies. In another, it has been suggested that quality of life is enhanced by LTG treatment, although this may simply be a function of reduced seizure numbers and severity.

Other antiepileptic drug concentrations were unaffected by LTG. In particular, there was no change in carbamazepine 10, 11 epoxide, the active metabolite of carbamazepine, which was thought to increase in a recent open study with similar LTG doses.7 We therefore postulate a pharmacodynamic mechanism for the well described interaction between LTG and carbamazepine.

This small study suggests substantial efficacy for an antiepileptic drug regimen containing VGB and LTG with a significant overall reduction in seizure days and numbers. Analysis of seizure type confirmed an effect on both partial and secondary generalised seizures. On the highest LTG dose (200 mg daily), 45% of patients documented at least 50% seizure reduction. The mean equivalent figure for the eight published placebo controlled, crossover trials is 22%. In a parallel group study among 216 patients with refractory partial seizures randomly assigned to an additional 300 mg or 500 mg LTG daily or placebo, only the higher LTG dose resulted in a significant fall in seizure numbers. The 500 mg dose produced a 50% seizure reduction in only 34% of patients compared with 45% with 200 mg LTG daily in our study.

The maximum dose of LTG employed in our study was only 200 mg daily, which is lower than that used in most published trials. Nevertheless, this resulted in a fall in seizures of 37% with 45% of the patients reporting greater than 50% seizure reduction. Scope, therefore, remained to increase the LTG dose further. Eight of the responders are currently taking 400–500 mg LTG daily and undergoing withdrawal of their standard anticonvulsant drugs to leave them on VIG and LTG only. So far, five of these patients are seizure free. Interestingly, synergism has been suggested for LTG in combination with sodium valproate, another drug thought to act by potentiating GABA-ergic inhibition.

Combining drugs with complementary modes of action may provide a rational pharmacological approach to the management of refractory epilepsy.

Our thanks go to Mrs Moya Dewar for expert secretarial assistance and to Dr AWC Yuen from the Wellcome Trust for supplying the lamotrigine and placebo tablets.

924

7 Grant SM, Heel RC. Vigabatrin. Drugs 1992;41:889-926.